Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Cefalonium bp (as cefalonium dihydrate)
Norbrook Laboratories Limited
QJ51DB90
Cefalonium bp (as cefalonium dihydrate)
250 mg/syringe
Intramammary suspension
POM: Prescription Only Medicine as defined in relevant national legislation
Cattle
cefalonium
Antibacterial
Authorised
2017-12-15
Health Products Regulatory Authority 07 June 2018 CRN000YF7 Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cepritect 250 mg Intramammary Suspension for Dry Cows 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Each intramammary syringe of 3g contains Cefalonium (as Cefalonium Dihydrate) 250 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Intramammary Suspension. Homogeneous white to beige coloured suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dairy cattle (dry cow) 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of subclinical mastitis at drying-off and the prevention of new bacterial infections of the udder during the non-lactating period of cows caused by _Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, _ _Streptococcus uberis, Trueperella pyogenes, Escherichia coli _and _Klebsiella spp. _ susceptible to cefalonium. 4.3 CONTRAINDICATIONS Do not use in animals with known hypersensitivity to cephalosporins, other β-lactam antibiotics or to any of the excipients. Please refer to section 4.7 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. Health Products Regulatory Authority 07 June 2018 CRN000YF7 Page 2 of 7 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to cefalonium and may decrease the effectiveness of treatment with other beta lactams. The efficacy of the product is only established against the pathogens mentioned in section 4.2 of the SPC. Consequently, serious acute mastitis (potentially fatal) due to other pathogen species, particularly _Pseudomonas aeruginosa_, can occu Read the complete document